{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-018203","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2023-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.912794+00:00","generated_at":"2026-06-20T06:45:56.543739+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Vera Therapeutics announces positive per-protocol analysis from Phase 2b ORIGIN trial of atacicept in IgA nephropathy","bullets":["At Week 24, atacicept 150 mg achieved 41% mean reduction in proteinuria and 34% delta vs placebo (p=0.025).","At Week 36 interim, atacicept 150 mg showed 47% mean reduction from baseline and 48% delta vs placebo.","Serious treatment-emergent AEs occurred in 2% of atacicept patients vs 9% in placebo; discontinuation rate 1%.","Company plans to advance atacicept into pivotal Phase 3 in first half of 2023, after FDA discussions.","Prespecified per-protocol analysis excluded 14 patients with protocol violations identified by blinded CRO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-018203","json":"https://secwatch.observer/filing/0001193125-23-018203.json","markdown":"https://secwatch.observer/filing/0001193125-23-018203.md","text":"https://secwatch.observer/filing/0001193125-23-018203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000119312523018203/0001193125-23-018203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000119312523018203/d381437d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T06:45:56.543739+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}